Duet BioTherapeutics

A Scopus BioPharma company creating targeted immunotherapies for treatment-resistant cancers. #immunooncology #oligonucleotides #STAT3

[Duet BioTherapeutics @DuetThera]

We are excited to share a new animation that explains how the Duet therapies work.

https://t.co/QfnhckUmJb

[Duet BioTherapeutics @DuetThera]

We're looking forward to @sitcancer's SITC 2023. Duet's co-founder, @kortylmt, will be presenting new data on how our oligos can be used to sensitize tumors for improved treatment with anti-PD-1 checkpoint blockade.

https://t.co/smbKB6kut1

[Oligonucleotide Therapeutics Society @OTSociety]

Day 1 Session Highlights!

To view the Oligo Meeting Agenda visit https://t.co/URf99oleeV.

#ots23 #ots #oligomeeting #oligotherapeutics #careers #biotech #biotechnology #science #research #biochemistry #medicine #health #biotechnology #barcelona #pharmaceuticals #networking

[Duet BioTherapeutics @DuetThera]

We're looking forward to OTS 2023 where @horsager will be co-chairing a panel on startups and commercialization in the oligonucleotide space.We have a great panel ranging from startup founders to VC to Pharma BD. Hope you can join us!

https://t.co/fEfLV1jubd

[Duet BioTherapeutics @DuetThera]

Attending BIO 2023? Click below to send Duet BioTherapeutics a meeting request in the BIO partnering system!

#BIO2023

https://t.co/8ghWqsq9va

[Duet BioTherapeutics @DuetThera]

We're looking forward to presenting at the 4th Annual RNAi-Based Therapeutics Summit!

[Duet BioTherapeutics @DuetThera]

Duet Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

https://t.co/HHIRxKysAu

[Duet BioTherapeutics @DuetThera]

Duet's Parent Company Scopus BioPharma Completes Recapitalization Designed To Enhance Shareholder Value

https://t.co/g95Ah6uAJc

[💸STOCKBALLA💸 @stockballa]

Low vol name but this $SCPS news is massive. $25m valuation $5m mkt cap.

[HealthEconomics.com | A Scientist.com Company @www_healthecon]

AstraZeneca Acquires T Cell Biotech TeneoTwo in $1.27 Billion Deal

https://t.co/8As6gtliaV

#HEOR #TCell #Therapeutics #MandAs #Biotech

[Duet BioTherapeutics @DuetThera]

Duet's Parent Company Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors #biotechnology #biopharma #leader

https://t.co/jPHs0aPgaZ

[The ASCO Post @ASCOPost]

Are Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer? https://t.co/mAZCSw9jJs #HNCSM #oncology #radonc #cancer #healthequity

[The ASCO Post @ASCOPost]

Newly redesigned Advances in Cancer Immunotherapy educational series from the Society for Immunotherapy of Cancer, free for healthcare professionals in the clinical setting, students and patient advocates https://t.co/g73ms5DRXF @sitcancer
#Immunotherapy #cancer #oncology

[Duet BioTherapeutics @DuetThera]

@erikrtn @UCLA @Caltech @JeffreyLowMD @kulesatony @sk_leung @ShahramSN @zavaindar @zebulgar @SaraNayeem @nxpatel Please DM me @horsager. I may have something more unique and interesting than VC, depending on what your friend is looking for. Based in Pasadena as well.

[Duet BioTherapeutics @DuetThera]

Here is a good primer for those less familiar with the therapeutic potential of RNA. And it's not just mRNA, it's oligonucleotides more broadly that have massive potential in how we think about addressing various diseases.

#oligonucleotides #STAT3

https://t.co/kVR4lkoSoK

[Duet BioTherapeutics @DuetThera]

Our presentation on Scopus BioPharma (@ScopusSCPS) and Duet Therapeutics will be tomorrow (Tuesday) at 8 AM PST. This will be our first in-person presentation at a conference since pre-Covid.

Let's all cross our fingers to have many more of these going forward!

[Duet BioTherapeutics @DuetThera]

We're very excited to present (in-person!!!) at the LD Micro Main Event to be held here, in Los Angeles, starting today.

https://t.co/yz6nEFol3B

[Duet BioTherapeutics @DuetThera]

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study

https://t.co/KYV8aYCEz0

[Duet BioTherapeutics @DuetThera]

Good to see that bifunctional molecules, which provide for cell-specific targeting and delivery of therapeutic agents, are gaining further traction in the marketplace.

#oligonucleotides #Immunotherapy #STAT3

https://t.co/R1WTJdhQSr

[Duet BioTherapeutics @DuetThera]

Very exciting to see this coming. These RNA-based therapies have revolutionized how we address infectious disease. Excited to see how oligonucleotides will impact how we treat cancer in the coming years. https://t.co/Colct9zbuI

[Sara Nayeem @SaraNayeem]

If you have a targeted oncology program, be prepared for investors to ask about several points: what is the level of expression of the target in (or on) tumor cells across tumor types, vs. healthy cells? Is this known at the protein level or transcript level or simply DNA...1/4